KCNK3 and atrial fibrillation: It is currently under study in the doxapram conversion to sinus rhythm (DOCTOS) trial, which will reveal whether doxapram, a potent TASK-1 inhibitor, can be used for acute cardioversion of persistent and paroxysmal AF in patients, potentially leading to a new treatment option for AF [143].